Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the sale, the chief executive officer owned 18,151 shares in the company, valued at approximately $477,189.79. This represents a 65.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $25.87 on Friday. The firm has a 50-day moving average price of $28.74 and a 200 day moving average price of $31.20. The firm has a market capitalization of $1.44 billion, a PE ratio of -10.27 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 52-week low of $14.16 and a 52-week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on MAZE shares. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds have recently made changes to their positions in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics during the first quarter worth approximately $145,000. Rhumbline Advisers acquired a new position in Maze Therapeutics in the first quarter worth approximately $80,000. Geode Capital Management LLC lifted its position in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after acquiring an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.